GlassScriptPhysician profile
Kailash Sharma
NPI 1407855083
$8,811.18
in general payments reported to CMS, 2019-2025
47 companies · $2,242 in 2025
The $2,242 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,834 · 2020: $304 · 2021: $1,090 · 2022: $1,397 · 2023: $1,053 · 2024: $891 · 2025: $2,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,186.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,665.91 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $1,492.08 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $583.17 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Genzyme Corporation | $410.30 | 2021-2025 | |
| Eisai INC. | $401.17 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $369.93 | 2019-2025 | Xifaxan, Relistor |
| Regeneron Healthcare Solutions, INC. | $337.18 | 2021-2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $326.42 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $276.44 | 2019-2025 | |
| Mylan Specialty L.P. | $235.78 | 2019-2022 | |
| Lilly USA, LLC | $227.93 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.37 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Radius Health, INC. | $217.83 | 2024-2025 | Tymlos |
| Abbvie INC. | $206.54 | 2021-2022 | |
| Amgen INC. | $179.53 | 2019-2025 | Tezspire |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $172.59 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $160.48 | 2019-2020 | |
| Electromed, INC. | $131.84 | 2022-2024 | Smartvest |
| Novartis Pharmaceuticals Corporation | $101.40 | 2019-2023 | |
| Grifols USA, LLC | $97.15 | 2021-2023 | Prolastin-C Liquid |
| Exact Sciences Corporation | $96.44 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $82.27 | 2019-2020 | |
| Axsome Therapeutics, INC. | $75.63 | 2023-2025 | Sunosi |
| Philips North America LLC | $68.28 | 2019-2025 | (Ak6) Vest Therapy, Comfortgel |
| Pulmonx Corporation | $65.23 | 2022-2023 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Harmony Biosciences LLC | $65.12 | 2023-2025 | Wakix |
| Idorsia Pharmaceuticals US INC | $51.03 | 2023 | Quviviq |
| Nalpropion Pharmaceuticals LLC | $46.58 | 2019 | |
| Verona Pharma, INC. | $44.98 | 2025 | Ohtuvayre |
| Kowa Pharmaceuticals America, INC. | $44.79 | 2019-2021 | |
| Circassia INC. | $43.83 | 2019 | |
| Insmed, INC. | $41.92 | 2025 | Arikayce |
| Pfizer INC. | $36.26 | 2019 | |
| Arbor Pharmaceuticals, INC. | $24.96 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $22.00 | 2023 | Eliquis |
| Inspire Medical Systems, INC. | $20.89 | 2024 | Inspire |
| Azurity Pharmaceuticals, INC. | $18.96 | 2023 | Horizant |
| Eyevance Pharmaceuticals LLC | $17.04 | 2021 | |
| Hikma Pharmaceuticals USA | $17.04 | 2021 | |
| Aytu Biopharma, INC. | $15.24 | 2020 | |
| Inogen, INC. | $14.63 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $14.47 | 2021 | |
| Ironwood Pharmaceuticals, INC | $14.12 | 2019 | |
| Amarin Pharma, INC. | $13.96 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.87 | 2025 | Glassia |
| Merck Sharp & Dohme LLC | $12.48 | 2019 | |
| Currax Pharmaceuticals LLC | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kailash Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.